|
XL092 Clinical Trials
3 actively recruiting trials across 3 locations
No change since May 2026
Also known as: Zanzalintinib
Pipeline
Phase 1: 1Phase 2: 2
Top Sponsors
- University of Utah1
- UNC Lineberger Comprehensive Cancer Center1
- Karie Runcie1
Indications
- Cancer3
- Advanced Renal Cell Carcinoma1
- Clear Cell Renal Cell Carcinoma1
- Metastatic Renal Cell Carcinoma1
- Metastatic Castration-resistant Prostate Cancer1
La Jolla, California1 trial
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
University of California San Diego
Phase 2
Boston, Massachusetts1 trial
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Dana Farber/Harvard Cancer Center
Phase 1
Salt Lake City, Utah1 trial
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Huntsman Cancer Institute at University of Utah
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.